"versionIdentifier","id","uuid:ID","rationale","instanceType"
"2","StudyVersion_1","2dc0931d-9f18-4ce7-8616-d98a5e9a1470","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion"
